Shuttle Pharmaceuticals shareholders vote to rename company United Compute Inc., approve merger share issuances

Shareholders voted to replace a pharmaceutical company name with a computing one. That vote required an amendment to the certificate of incorporation, the founding legal document that records a corporation's official identity with the state. At a special meeting held September 9, 2026, stockholders of Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) approved renaming the company United Compute Inc., with 576,928 shares in favor and 10,868 against.

The meeting drew 588,987 of the company's 1,027,214 outstanding shares, about 57.33% of the total. That share count satisfied the quorum, or minimum attendance threshold, needed for the vote to be binding.

What the ballot actually covered

The name change was one of five proposals. Four required a simple majority of shares present and voting. The name change required a majority of all outstanding shares, a higher threshold.

Two proposals authorized Shuttle to issue millions of new shares tied to a merger agreement with United Dogecoin Inc., signed April 30, 2026. Nasdaq Listing Rule 5635 requires listed companies to seek shareholder approval before issuing shares above certain thresholds, so the votes were a legal prerequisite for the transactions to proceed.

Proposal 1 covered Series B-1 Preferred Stock connected to the United Dogecoin merger. Under it, Shuttle could issue up to approximately 3,389,337 shares through stock conversion, plus pre-funded warrants exercisable for up to approximately 12,292,752 additional shares. Pre-funded warrants are contracts giving the holder the right to buy shares at a near-zero exercise price, with most of the cost paid upfront at issuance. The proposal also covered shares tied to a Second Amendment to an Asset Purchase Agreement and shares issued to E.F. Hutton and Co. as a financial advisory fee on the merger. It passed 442,624 to 11,145.

Proposal 2 addressed a Securities Purchase Agreement, also dated April 30, 2026. It authorized up to approximately 927,114 shares through Series B-2 Preferred Stock conversion, a matching allotment through common stock purchase warrants, and pre-funded warrants exercisable for up to approximately 3,148,619 shares. That proposal passed 442,193 to 11,579.

Proposal 3 expanded the company's 2018 Equity Incentive Plan, raising the total shares authorized for employee and director grants to 8,800,000. It passed 428,743 to 25,023.

The filing was signed September 11, 2026, by Christopher Cooper, Co-Chief Executive Officer of Shuttle Pharmaceuticals Holdings, at the company's offices at 401 Professional Drive, Suite 260, Gaithersburg, Maryland.